Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

Yourgene Health Receives HSA approval for IONA Nx NIPT Workflow in Singapore

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

Yourgene Health plc (“Yourgene”, AIM: YGEN), a leading international molecular diagnostics group, today announced it has received Health Sciences Authority (HSA) approval for its IONA® Nx NIPT Workflow in Singapore.

The prenatal screening workflow has been authorized for use in clinical laboratories, providing them with a fully automated and cost-effective testing solution to establish their own fast, accurate and quality-assured non-invasive prenatal testing (NIPT) service. Yourgene’s optimized NIPT solution enables efficient workflows, helping to save laboratories time, money and enhance their performance.

The IONA Nx NIPT Workflow is an in vitro diagnostic (IVD) tool designed to offer flexibility, simplicity and scalability for prenatal screening. The fully validated workflow uses next-generation sequencing (NGS)-based whole genome analysis to screen for a wide range of clinical conditions in the fetus, including Down’s syndrome (Trisomy 21), Edwards’ syndrome (Trisomy 18) or Patau’s Syndrome (Trisomy 13). It can also be used to screen for autosomal- and sex-chromosome aneuploidies, as well as providing the option of fetal sex determination from 10 weeks gestation. The complete workflow includes sample preparation, DNA extraction and library construction, requiring minimal fetal fraction, as well as sequencing analysis and clinical reporting with full sample traceability.

The approval of the workflow in Singapore will help to expand patient access to non-invasive prenatal screening and provide laboratories with choice as to which IVD NIPT services they are able to offer clinicians. The regulatory authorisation adds to the IONA Nx’ existing accreditations, including a CE mark, and now means the workflow is available in many countries across Europe, the Middle East and Asia.

Rob Henke, PhD, Vice President of Sales, Asia Pacific, Yourgene Health, said: “By expanding into Singapore’s market, we are able to provide more laboratories access to our technology and, ultimately, offer more patients NIPT as a first call over higher-risk procedures. Expanding further into Asia, with the help of our distributor SDT Molecular, is an exciting milestone for Yourgene, as we continue to establish new revenue opportunities and grow our international customer base.

Shirley Tan, CEO of SDT Molecular, added: “We are honoured to be given the opportunity to help Yourgene obtain HSA approval for their IVD NIPT solution in Singapore. This marks an important milestone for SDT Molecular and we look forward to working closely with Yourgene, to allow more clinical laboratories in the region to benefit from this IVD offering.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine